Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RNAZBullishResearch Analysisnews

High materiality7/10

Cancers study on miR-10b boosts TransCode's RNAZ candidate viability

Aug 31, 2026, 8:07 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Peer-reviewed preclinical validation can lift confidence in the RNAZ platform, potentially accelerating partnership interest and future funding, though translation and clinical risk remain.

AI summary

What happened, with direct paths to the underlying reporting

A peer-reviewed article in Cancers reports that TTX-MC138 accumulates in bone metastases and extends survival in a mouse model by inhibiting miR-10b, supporting TransCode's RNA-based approach. While translational hurdles remain, findings reinforce potential expansion of RNAZ platform into metastatic cancers beyond colorectal disease.

Publication online Aug 23, 2026 in Cancers. Peer-reviewed validation of miR-10b targeting.
TTX-MC138 accumulates in metastatic bone lesions after systemic administration.
Inhibits miR-10b and increases HOXD10 expression.
Survival benefits observed in a breast cancer bone metastasis mouse model.
No systemic toxicity observed; dosing well tolerated.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.